Shares of Pacira BioSciences are down $10.66, or 48%, to $11.70 after the company announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495 for Exparel is not valid.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
- Pacira price target lowered to $37 from $41 at Raymond James
- Pacira price target lowered to $37 from $42 at RBC Capital
- Pacira backs FY24 revenue view $680M-$705M, consensus $694.66M
- Pacira reports Q2 EPS 89c, consensus 70c